Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

0 have gone public and more than 250 have been acquired. NEA has U.S. offices in Chevy Chase, Maryland; Menlo Park, California; and Baltimore, Maryland. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trial evaluating Amicus' candidate drug products, and the timing of updates on the interactions with the FDA on the AT2220 program. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate,"
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Lisa Kulik saw fireworks ... July 4 holiday, thanks to a groundbreaking retinal implant ... internationally renowned clinician-researcher at the University of Southern California ... Peoria, Ariz. resident who has ... victims of sight. On June 2, she became the ...
(Date:8/27/2014)... Mass. (PRWEB) August 27, 2014 “We ... top technology vendors,” said Ven Thangaraj, CEO of Radiant ... solutions that are taking the imaging corelab market to ... sponsors, corelabs and research organizations to efficiently and effectively ... prepare the data to be analyzed and read by ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Nov. 16, 2010 Scientists from Chimerix, Inc. ... that the company,s lipid-conjugated drugs, CMX001 and CMX157, ... Transporters (hOATs) and thus have significantly reduced potential ... presented at the International Pharmaceutical Federation (FIP) Pharmaceutical ...
... ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... 16, 2010 Syngenta has announced the winners of ... Zoltan Balogh from Hungary and Mario Pereda from Spain ... $8000, $5000 and $3000, respectively. The winning photos were ... their quality, creativity and interpretation of Syngenta,s purpose: Bringing ...
Cached Biology Technology:Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4Enerkem adds two new executive roles to growing North American presence 2Enerkem adds two new executive roles to growing North American presence 3Enerkem adds two new executive roles to growing North American presence 4Enerkem adds two new executive roles to growing North American presence 5Enerkem adds two new executive roles to growing North American presence 6Enerkem adds two new executive roles to growing North American presence 7Syngenta Announces Photo Prize 2010 Winners 2
(Date:8/27/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that ... of units of common stock and warrants at a ... $20 million, prior to deducting underwriting discounts and commissions ... and warrants are immediately separable and will be issued ... offering consists of 2,000 shares of common stock and ...
(Date:8/27/2014)... big step in understanding the mysteries of the human ... analyses that provide the most detailed comparison yet of ... human function. , The research, appearing August 28 ... the information encoded in the three species, genomes is ... organized into chromosomes. , The results add billions of ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... is available in its catalogue: Law ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html About ... assess individuals on the basis of their physical ... identification of both physiological traits such as fingerprints, ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... mapping of the entire yeast genome in 1996 marked the ... human genome was mapped in 2001, and by now the ... are bacteria. The next advance is only a few years ... including humans. "We shall then be able to identify ...
... is available in German . , A ... already been shown in the past. Scientists at the universities ... first evidence of a shared genetic variant on chromosome 9, ... "antisense RNA" Anril, as reported in the latest edition of ...
... with dementia suffer from Alzheimer,s disease. Estimates indicate that ... Alzheimer,s patients. Alzheimer,s is a disease that gradually destroys ... of patients with Alzheimer,s gradually declines. At first, memory ... deteriorate as the disease progresses. Today, this disease cannot ...
Cached Biology News:Genetic differences between yeasts greater than those between humans and chimpanzees 2New target for medicine to combat Alzheimer's: VIB scientists confirm protein's key role 2
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: